352 related articles for article (PubMed ID: 33964007)
1. Graves' disease and Graves' orbitopathy following COVID-19.
Lanzolla G; Marcocci C; Marinò M
J Endocrinol Invest; 2021 Sep; 44(9):2011-2012. PubMed ID: 33964007
[No Abstract] [Full Text] [Related]
2. Graves' orbitopathy post-SARS-CoV-2 vaccines: report on six patients.
Abeillon-du Payrat J; Grunenwald S; Gall E; Ladsous M; Raingeard I; Caron P
J Endocrinol Invest; 2023 Mar; 46(3):617-627. PubMed ID: 36378488
[TBL] [Abstract][Full Text] [Related]
3. Genetic immunization with mouse thyrotrophin hormone receptor plasmid breaks self-tolerance for a murine model of autoimmune thyroid disease and Graves' orbitopathy.
Schlüter A; Horstmann M; Diaz-Cano S; Plöhn S; Stähr K; Mattheis S; Oeverhaus M; Lang S; Flögel U; Berchner-Pfannschmidt U; Eckstein A; Banga JP
Clin Exp Immunol; 2018 Mar; 191(3):255-267. PubMed ID: 29058307
[TBL] [Abstract][Full Text] [Related]
4. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
[TBL] [Abstract][Full Text] [Related]
5. Concurrent pretibial myxedema and thyroid eye disease following mRNA COVID-19 vaccine in a patient with history of Graves' disease.
Caron P; Imbert P; Dekeister C; Grunenwald S
Ann Endocrinol (Paris); 2024 Apr; 85(2):100-103. PubMed ID: 37866430
[TBL] [Abstract][Full Text] [Related]
6. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
7. Can autoimmunity against calsequestrin explain the eye and eyelid muscle inflammation of thyroid eye disease?
Gopinath B; Wescombe L; Nguyen B; Wall JR
Orbit; 2009; 28(4):256-61. PubMed ID: 19839885
[TBL] [Abstract][Full Text] [Related]
8. Development of Graves' Disease After SARS-CoV-2 mRNA Vaccination: A Case Report and Literature Review.
Lui DTW; Lee KK; Lee CH; Lee ACH; Hung IFN; Tan KCB
Front Public Health; 2021; 9():778964. PubMed ID: 34888290
[No Abstract] [Full Text] [Related]
9. Pathogenesis of Graves' disease focusing on Graves' ophthalmopathy.
Karoutsou E; Polymeris A
Endocr Regul; 2011 Oct; 45(4):209-20. PubMed ID: 22073951
[No Abstract] [Full Text] [Related]
10. Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor.
Plöhn S; Hose M; Schlüter A; Michel L; Diaz-Cano S; Hendgen-Cotta UB; Banga JP; Bechrakis NE; Hansen W; Eckstein A; Berchner-Pfannschmidt U
Thyroid; 2019 Sep; 29(9):1286-1301. PubMed ID: 31237525
[TBL] [Abstract][Full Text] [Related]
11. Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials.
Banga JP; Nielsen CH; Gilbert JA; El Fassi D; Hegedus L
Thyroid; 2008 Sep; 18(9):973-81. PubMed ID: 18752425
[TBL] [Abstract][Full Text] [Related]
12. Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases.
Molnár I; Bokk A
Cytokine; 2006 Aug; 35(3-4):109-14. PubMed ID: 17008110
[TBL] [Abstract][Full Text] [Related]
13. Occurrence of Graves' hyperthyroidism and Graves' orbitopathy after fine-needle aspiration biopsy of thyroid nodules.
Lanzolla G; Marcocci C; Marinò M
J Endocrinol Invest; 2020 Jul; 43(7):1033-1034. PubMed ID: 32077044
[No Abstract] [Full Text] [Related]
14. Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease.
Gopinath B; Musselman R; Beard N; El-Kaissi S; Tani J; Adams CL; Wall JR
Clin Exp Immunol; 2006 Jul; 145(1):56-62. PubMed ID: 16792674
[TBL] [Abstract][Full Text] [Related]
15. Management of Graves' hyperthyroidism and orbitopathy in time of COVID-19 pandemic.
Bartalena L; Chiovato L; Marcocci C; Vitti P; Piantanida E; Tanda ML
J Endocrinol Invest; 2020 Aug; 43(8):1149-1151. PubMed ID: 32441005
[No Abstract] [Full Text] [Related]
16. Peripheral T and B lymphocytes do not correlate with Graves' orbitopathy.
Ionni I; Rotondo Dottore G; Marinò M
J Endocrinol Invest; 2018 Nov; 41(11):1355-1356. PubMed ID: 30182361
[No Abstract] [Full Text] [Related]
17. The autoimmunity in Graves's disease.
Li H; Wang T
Front Biosci (Landmark Ed); 2013 Jan; 18(2):782-7. PubMed ID: 23276963
[TBL] [Abstract][Full Text] [Related]
18. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
[TBL] [Abstract][Full Text] [Related]
19. New-onset Thyroid Eye Disease after COVID-19 Vaccination in a Radioactive Iodine-Treated Graves' Disease Patient: A Case Report and Literature Review.
Im Teoh JH; Mustafa N; Wahab N
J ASEAN Fed Endocr Soc; 2023; 38(1):125-130. PubMed ID: 37252417
[TBL] [Abstract][Full Text] [Related]
20. Re: "Thyroid Eye Disease Following COVID-19 Vaccine in a Patient With a History Graves' Disease: A Case Report".
Sriwijitalai W; Wiwanitkit V
Ophthalmic Plast Reconstr Surg; 2022 Jan-Feb 01; 38(1):95. PubMed ID: 34982065
[No Abstract] [Full Text] [Related]
[Next] [New Search]
